ZIMV
ZIMV
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $116.662M ▲ | $74.017M ▲ | $-3.947M ▼ | -3.383% ▼ | $-0.14 ▼ | $12.729M ▼ |
| Q1-2025 | $111.997M ▲ | $73.268M ▼ | $-1.471M ▲ | -1.313% ▲ | $-0.05 ▲ | $13.156M ▲ |
| Q4-2024 | $111.521M ▲ | $79.144M ▲ | $-11.766M ▼ | -10.55% ▼ | $-0.43 ▼ | $7.144M ▼ |
| Q3-2024 | $103.222M ▼ | $72.239M ▼ | $-2.284M ▲ | -2.213% ▲ | $-0.08 ▲ | $9.871M ▲ |
| Q2-2024 | $116.811M | $79.981M | $-4.014M | -3.436% | $-0.15 | $6.775M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $70.176M ▲ | $758.224M ▲ | $345.423M ▼ | $412.801M ▲ |
| Q1-2025 | $66.75M ▼ | $745.782M ▼ | $350.659M ▼ | $395.123M ▲ |
| Q4-2024 | $74.974M ▲ | $753.674M ▼ | $371.967M ▼ | $381.707M ▼ |
| Q3-2024 | $66.808M ▼ | $782.948M ▼ | $376.31M ▼ | $406.638M ▲ |
| Q2-2024 | $78.601M | $789.786M | $395.687M | $394.099M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-3.947M ▼ | $3.229M ▲ | $-7.43M ▼ | $426K ▲ | $3.426M ▲ | $1.654M ▲ |
| Q1-2025 | $-1.471M ▲ | $-13.911M ▼ | $-1.947M ▲ | $-1.135M ▼ | $-9.822M ▼ | $-15.414M ▼ |
| Q4-2024 | $-11.766M ▼ | $21.45M ▲ | $-2.873M ▼ | $776K ▲ | $8.476M ▲ | $18.761M ▲ |
| Q3-2024 | $-2.284M ▲ | $1.199M ▼ | $-530K ▼ | $-18.771M ▲ | $-14.599M ▼ | $615K ▼ |
| Q2-2024 | $-9.553M | $3.036M | $289.837M | $-275.233M | $14.111M | $1.778M |
Revenue by Products
| Product | Q4-2022 | Q1-2023 | Q2-2023 | Q3-2023 |
|---|---|---|---|---|
 Dental | $120.00M ▲ | $120.00M ▲ | $120.00M ▲ | $110.00M ▼ |
 Segment Total | $230.00M ▲ | $230.00M ▲ | $220.00M ▼ | $200.00M ▼ |
 Spine | $110.00M ▲ | $100.00M ▼ | $110.00M ▲ | $100.00M ▼ |
About ZimVie Inc.
https://www.zimvie.comZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $116.662M ▲ | $74.017M ▲ | $-3.947M ▼ | -3.383% ▼ | $-0.14 ▼ | $12.729M ▼ |
| Q1-2025 | $111.997M ▲ | $73.268M ▼ | $-1.471M ▲ | -1.313% ▲ | $-0.05 ▲ | $13.156M ▲ |
| Q4-2024 | $111.521M ▲ | $79.144M ▲ | $-11.766M ▼ | -10.55% ▼ | $-0.43 ▼ | $7.144M ▼ |
| Q3-2024 | $103.222M ▼ | $72.239M ▼ | $-2.284M ▲ | -2.213% ▲ | $-0.08 ▲ | $9.871M ▲ |
| Q2-2024 | $116.811M | $79.981M | $-4.014M | -3.436% | $-0.15 | $6.775M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $70.176M ▲ | $758.224M ▲ | $345.423M ▼ | $412.801M ▲ |
| Q1-2025 | $66.75M ▼ | $745.782M ▼ | $350.659M ▼ | $395.123M ▲ |
| Q4-2024 | $74.974M ▲ | $753.674M ▼ | $371.967M ▼ | $381.707M ▼ |
| Q3-2024 | $66.808M ▼ | $782.948M ▼ | $376.31M ▼ | $406.638M ▲ |
| Q2-2024 | $78.601M | $789.786M | $395.687M | $394.099M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-3.947M ▼ | $3.229M ▲ | $-7.43M ▼ | $426K ▲ | $3.426M ▲ | $1.654M ▲ |
| Q1-2025 | $-1.471M ▲ | $-13.911M ▼ | $-1.947M ▲ | $-1.135M ▼ | $-9.822M ▼ | $-15.414M ▼ |
| Q4-2024 | $-11.766M ▼ | $21.45M ▲ | $-2.873M ▼ | $776K ▲ | $8.476M ▲ | $18.761M ▲ |
| Q3-2024 | $-2.284M ▲ | $1.199M ▼ | $-530K ▼ | $-18.771M ▲ | $-14.599M ▼ | $615K ▼ |
| Q2-2024 | $-9.553M | $3.036M | $289.837M | $-275.233M | $14.111M | $1.778M |
Revenue by Products
| Product | Q4-2022 | Q1-2023 | Q2-2023 | Q3-2023 |
|---|---|---|---|---|
| Dental | $120.00M ▲ | $120.00M ▲ | $120.00M ▲ | $110.00M ▼ |
| Segment Total | $230.00M ▲ | $230.00M ▲ | $220.00M ▼ | $200.00M ▼ |
| Spine | $110.00M ▲ | $100.00M ▼ | $110.00M ▲ | $100.00M ▼ |
CEO
Vafa Jamali
Compensation Summary
(Year 2024)
CEO
Vafa Jamali
Compensation Summary
(Year 2024)
Most Recent Analyst Grades
Grade Summary
Price Target
Institutional Ownership
GLAZER CAPITAL, LLC
2.294M Shares
$43.571M
EVERSEPT PARTNERS, LP
2.079M Shares
$39.487M
BLACKROCK, INC.
1.953M Shares
$37.091M
BLACKROCK INC.
1.823M Shares
$34.624M
VANGUARD GROUP INC
1.631M Shares
$30.975M
CAMBER CAPITAL MANAGEMENT LP
1.6M Shares
$30.384M
KENT LAKE CAPITAL LLC
1.25M Shares
$23.737M
FIL LTD
1.128M Shares
$21.429M
UBS GROUP AG
1.098M Shares
$20.845M
MORGAN STANLEY
826.452K Shares
$15.694M
GAMCO INVESTORS, INC. ET AL
788.583K Shares
$14.975M
AMERICAN CENTURY COMPANIES INC
746.912K Shares
$14.184M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
702.595K Shares
$13.342M
NEUBERGER BERMAN GROUP LLC
691.669K Shares
$13.135M
GEODE CAPITAL MANAGEMENT, LLC
680.001K Shares
$12.913M
DIMENSIONAL FUND ADVISORS LP
673.443K Shares
$12.789M
FIRST TRUST CAPITAL MANAGEMENT L.P.
636.209K Shares
$12.082M
MAGNETAR FINANCIAL LLC
603.489K Shares
$11.46M
STATE STREET CORP
573.401K Shares
$10.889M
SOLAS CAPITAL MANAGEMENT, LLC
530.013K Shares
$10.065M
Summary
Only Showing The Top 20